Multiple myeloma (MM), a cancer of terminally differentiated plasma cells, is the second
most common hematological malignancy. The disease is characterized by the accumulation …

The last decade has encountered an increasing demand for plant-based natural antibiotics.
This demand has led to more research-based investigations for natural sources of …

Glutamoptosis is the induction of apoptotic cell death as a consequence of the aberrant
activation of glutaminolysis and mTORC1 signaling during nutritional imbalance in …

Resistance to chemotherapy, a major therapeutic challenge in the treatment of T-cell acute
lymphoblastic leukemia (T-ALL), can be driven by interactions between leukemic cells and …

Primary malignant melanoma of esophagus is very rare, and its clinicopathologic and
genetic features have not been extensively investigated. In this study, 20 tumors from 14 …

Metformin is a biguanide molecule used since 1957 to treat type 2 diabetes patients. In
addition to its hypoglycemic effects, epidemiological studies have shown that metformin can …

The mTOR is a central regulator of cell growth and is highly activated in cancer cells to allow
rapid tumor growth. The use of mTOR inhibitors as anticancer therapy has been approved …

Cardamonin exhibits a variety of pharmacological activities including anti-inflammatory and
antitumor, which are correlated with the inhibition of nuclear factor-kappaB and the …

Mechanistic target of rapamycin (MTOR) is a highly conserved serine/threonine kinase that
critically regulates cell growth, proliferation, differentiation, and survival. Previously, we have …

Chemotherapy can eradicate a majority of cancer cells. However, a small population of
tumor cells often survives drug treatments through genetic and/or non-genetic mechanisms …